Sanofi (EPA:SAN)
France
· Delayed Price · Currency is EUR 83.32
-0.01 (-0.01%)
Jul 9, 2025, 5:35 PM CET
Sanofi Revenue
Sanofi had revenue of 10.61B EUR in the quarter ending March 31, 2025, a decrease of -4.61%. This brings the company's revenue in the last twelve months to 45.17B, down -2.42% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.17B
Revenue Growth
-2.42%
P/S Ratio
2.25
Revenue / Employee
544.97K
Employees
82,878
Market Cap
101.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 26.51B |
| Sartorius Stedim Biotech | 2.86B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 6.95B |
| Ipsen | 3.57B |
| Virbac | 1.40B |
| Clariane SE | 5.28B |
| emeis Société anonyme | 5.64B |
Sanofi News
- 7 hours ago - Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug - Benzinga
- 2 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY - PRNewsWire
- 7 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY - PRNewsWire
- 8 days ago - Adagene gains as Sanofi collaboration expands - Seeking Alpha
- 9 days ago - Press release: Availability of the Q2 2025 Aide mémoire - GlobeNewsWire
- 9 days ago - Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy - GlobeNewsWire
- 12 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY - PRNewsWire
- 13 days ago - Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts - PRNewsWire